Phase 1 study of the safety and tolerability of single ascending doses of the novel oral CCR2 antagonist CNTX-6970 in healthy volunteers

Authors
Category Primary study
ConferencePain Medicine (United States)
Year 2018
This article has no abstract
Epistemonikos ID: 89d30030a4b211cf8a83c6e3e705a936be140210
First added on: Apr 29, 2026